VBIV - הכנסה תפעולית לפני ניכוי פחת vbivaccines.com

VBI Vaccines Inc. (VBIV) maintains its resilience based on patent protection of VLP technologies for combating brain cancer and hepatitis B. The sale of approved drugs across various countries ensures a stable income stream. EBITDA cash flow reflects daily operational results, where the value of indicates the current magnitude. Its status as a technological leader is confirmed by a powerful R&D potential in the development of innovative eVLP-based antiviral vaccines.

The flexible production model of VBI Vaccines Inc. (VBIV), which combines its own facility in Canada with European CMO capacities, directly impacts operational efficiency. By analyzing EBITDA volatility, the investor assesses earnings before interest, taxes, depreciation, and amortization, which determines the business's actual ability to generate cash flow and confirms the asset's financial stability.